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Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in 
the treatment of patients with lower respiratory tract infections
Y. Mouton, O. Leroy, C. Beuscart, C. Chidiac, E. Senneville, F. Ajana, P. Lecocq 
and Study Group*
Service Régional des Maladies Infectieuses et du Voyageur 59208 Tourcoing, France
An open, non-com parative m ulticentre study was conducted  at 36 sites in six 
countries to test the efficacy and safety o f  piperacillin /tazobactam  in the therapy o f  
lower respiratory  tract infections. Piperacillin 4 g and  tazobactam  500 m g were
adm inistered intravenously every 8 h for a m inim um  o f  five days. Two hundred  and 
thirty  patients were enrolled: 133 were evaluable for clinical efficacy and 106 for 
bacteriological efficacy. The clinical response was favourable in 96%  o f  evaluable 
patients and  the bacterial eradication rate was 93% . N ine patients (4% ) had  severe 
adverse events related to piperacillin /tazobactam  and  requiring d iscontinuation  o f  
therapy. In this study piperacillin /tazobactam  was an effective and  safe drug in the 
trea tm ent o f  hospitalized patients with lower respiratory trac t infection caused by 
sensitive organisms.
Introduction
Piperacillin sodium is a broad-spectrum semisynthetic penicillin administered parenter- 
ally. It has been widely used in the treatment of serious lower respiratory tract 
infections (Winston et al., 1980; Gooding, Clark & Sathe, 1982; Mouton, Beuscart & 
Soussy, 1986). However, the spread of /2-lactamase producing organisms is a problem 
(Philippon, Paul & Nevot, 1987), especially among strains of Staphylococcus spp., 
Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli and Klebsiella spp.
In-vitro studies have shown that the /Mactamase inhibitor tazobactam restores the 
activity of piperacillin against /Mactamase producing staphylococci and a wide variety 
of resistant Gram-negative bacteria (Kuck et al., 1989; Weiss et al., 1989).
Since most pathogens isolated from lower respiratory tract infections can be expected 
to fall within the extended spectrum of activity of piperacillin/tazobactam, a prospec­
tive study was performed to test the efficacy and safety of this combination in the 
therapy of lower respiratory tract infections.
Patients and methods
From November 1988 to January 1990, an open non-comparative, multi-centre study 
was conducted in 36 hospitals, in six countries. This study was approved by appro-
*Study group: Mahieu (Belgium); Mehtar (UK); Aubertin, Carlet, Cartier, Domart, Dupeyron, Dureux, 
Erny, Gaillat, Garré, Gibert, Leophonte, Loirat, Mouton, Offenstadt, Portier, Pourrai, Rogez, Samii 
(France); Buchler, Christman, Daschner, Forycki, Herhain, Krier, Loweg, Milatovic (Germany); Van 
Breukelen, Van de Meer (Holland); Aguirre, De La Cebada, Fuentes de Toro, Gamboa y Gamboa, Ruiz 
Palacios, Zarala (Mexico).
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priate Ethics Committees and was conducted in accordance with the Declaration of 
Helsinski. Informed consent was obtained before enrolment of the patient.
Patient selection
t
Hospitalized patients with a minimum age of 18 years, suffering from a clinically or 
bacteriologically confirmed lower respiratory tract infection, caused by bacteria, 
thought to be susceptible to piperacillin/tazobactam, were eligible for entry into the 
study.
Clinical criteria for enrolment included the recent onset or increase in purulent 
sputum, a temperature of > 38°C and/or a peripheral white blood cell count of 
> 10,000/m3. Chest X-rays were required to classify a case of pneumonia as opposed to 
bronchitis. Female patients with child-bearing potential were enrolled if they had a 
negative pregnancy test within 24 h before enrolment and if they practised sexual 
abstinence or used a medically accepted form of birth control during the treatment 
period.
Patients were excluded in cases of: known allergy to /Mactam antibiotics or ^-lacta­
mase inhibitors; too severe lower respiratory tract infection (septic shock, use of 
mechanical ventilation with either a positive end-expiratory pressure > 5 cm H20  or 
an FiO: > 60%); concomitant use of probenecid or antibiotics; use of another 
antibacterial agent within the past 72 h (unless this had proved to be clinically and 
bacteriologically ineffective); presence of a pathogen known to be resistant to pipera­
cillin/tazobactam; presence of Pseudomonas aeruginosa', administration of any investi­
gational drug within one month before enrolment; severe renal impairment (serum 
creatinine > 225 mmol/L) serious hepatic disease (serum transaminases, alkaline phos­
phatase or bilirubin more than twice the normal upper limit); haematological disturb­
ances (leukaemia, granulocyte count < 1000/mm3 or platelet counts < 50,000/mm3). 
The patients with the following conditions were also excluded: cystic fibrosis; bronchial 
obstruction; lung abscess; empyema; lung cancer or metastastic lung disease; artificial 
heart valve or vascular prosthesis; tuberculosis or any other concomitant infection 
(except intra-abdominal infection); and AIDS or HIV antibody positivity.
Administration o f drug
Piperacillin 4 g and tazobactam 500 mg were administered every 8 h by intravenous 
infusion over 30 min. Each patient was to be treated for a minimum of five days 
although it was recommended that in patients who exhibited a satisfactory clinical 
response, treatment should be continued for at least two days after the resolution of 
signs and symptoms.
Study procedures
A complete medical history, physical examination and chest X-ray of the patient was 
performed before entry into the study. Evaluations to determine response to therapy 
were made daily for the first week of therapy; every two to three days thereafter during 
treatment; on the last day of therapy (end-point); one to three days (early follow-up) 
and ten to 14 days (late follow-up) after completion of therapy. A repeat chest x-ray 
was required only in patients with persisting clinical signs of active infections or in 
those who were withdrawn because of treatment failure or adverse reaction.
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Before the start of treatment cultures of blood and respiratory secretions were 
obtained to document the presence of pathogens. Additional cultures were taken after 
three to four days of therapy; one to three days and ten to 14 days post-treatment; and 
on the last day of treatment for patients withdrawn early from the study. 
Microorganisms were isolated and identified according to standard bacteriological 
methods. The degree of susceptibility to piperacillin/tazobactam was recorded for each 
pathogen.
The safety of piperacillin/tazobactam was judged by the following laboratory 
parameters: complete blood cell and differential leucocyte and platelet count; pro­
thrombin time; direct Coombs’ test; serum electrolytes, urea, creatinine, total bilirubin, 
alkaline phosphatase, transaminases (SGOT, SGPT), blood glucose, albumin, total 
protein and uric acid; and urinalysis and microscopy of the sediment. Laboratory 
evaluations were performed before treatment, every three to five days during treatment, 
one to three days and ten to 14 days post-treatment and on the last day of therapy if a 
patient was withdrawn early from the study.
Adverse clinical experiences during treatment were recorded and the relationship of 
the event to the study therapy assessed by the treating clinician.
Evaluation o f  therapy
To be considered for clinical efficacy, a patient must have met all the inclusion and 
exclusion criteria and should have had (a) treatment with piperacillin/tazobactam for at
*
least five days and (b) at least one end-of-therapy or post-therapy clinical evaluation.
Clinical response was classified as follows: (a) cure: the patient was asymptomatic 
with no evidence of active infection at the time treatment was completed and at the 
post-therapy evaluation; (b) improvement: significant improvement of symptoms on 
evaluation but with persisting evidence of infection (c) relapse: clinical improvement 
followed by deterioration during therapy or at the post-treatment evaluation (d) 
failure: no significant response to therapy or inability to tolerate the study drug.
For bacteriological evaluation, a patient must have met the clinical evaluability 
criteria as well as having had the following: (a) presence of pre-therapy pathogen(s) 
susceptible to piperacillin/tazobactam; (b) availability of susceptibility data; (c) at least 
one end-of-therapy or post-therapy bacteriological evaluation. Bacteriological response 
was graded as follows: (a) eradication: the original pathogen(s) eradicated in culture 
taken during or after treatment (or presumptively eradicated based upon clinical 
response); (b) persistence: presence of the original pathogen(s) in culture taken during 
or after treatment; (c) superinfection (early follow-up) or reinfection (late follow-up): 
all baseline pathogens eradicated, but one or more new pathogens present in culture 
taken at early or late follow-up respectively.
Results
A total of 230 patients was enrolled. Of these, 133 (58%) were considered evaluable for 
clinical efficacy and 106 (46%) for bacteriological efficacy.
The primary reasons for non-evaluability are summarized in Table I. The 
predominant reason for exclusion from clinical evaluation was inadequate regimen 
{n = 2 0 ); 32 patients were excluded from bacteriological evaluation because no patho­
gen was isolated.
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Table I. Prim ary  reasons for clinical and bacteriological non-evaluability
R eason for exclusion
N u m b er o f  patients who 
Clinically
were not evaluable 
Bacteriologically
A bnorm al labora to ry  values before therapy 15 12
Resistant pathogen(s) before therapy 8 8
Pre-study antim icrobial therapy 15 12
Inadequate  signs and sym ptom s 14 14
C oncom itan t antim icrobial therapy 8 7
Inadequate  regimen 20 14
Missed visits 7 10
N o pathogen(s) isolated 32
N o susceptibility test 8
O ther 10 7
Total 97 124
Characteristics o f  patients
The ages and sexes of patients in the whole group (n = 230), the clinically evaluable 
group (n = 133) and the bacteriologically evaluable group (n = 106), were very similar. 
The commonest diagnosis was pneumonia followed by bronchitis and broncho­
pneumonia (Table II). Most infections were community-acquired, with a level of 52% 
(120/230) overall. This increased to 63% in the clinically evaluable group (84/133) and 
in the bacteriologically evaluable group (67/106). The mean duration of infections was 
6*0 days for all patients, 4-5 days for clinically evaluable patients and 4-9 days for 
bacteriologically evaluable patients.
Twenty-seven patients were treated with other antibacterial agents during the 72 h 
immediately preceding the initiation of the study medication; 2 2  of these patients were 
excluded from analysis. Of the remaining five patients, one received acceptable prophy­
laxis only and four had documented resistance to the antibacterial agents used.
Table II. C haracteristics o f  patients
Clinically Bacteriologically
C haracteristics
Total 
(n = 230)
evaluable patients
(n =  133)
evaluable patients 
(n =  106)
M ean age (years) 57-5 (S.D. 17-3) 55-6 (S.D. 18-0) 55-2 (S.D. 17-9)
R ange (years) 18-90 18-90 18-87
Sex
male 157 87 66
female 73 46 40
Diagnosis
Pneum onia 161 90 70
Bronchitis 36 25 21
B ronchopneum onia 21 11 9
A cute L R T I" 10 5 5
Pneum onia  with pleurisy 2 2 1
u LRTI, Lower respiratory tract infection; site of infection not determined.
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Table III. Pathogens isolated before therapy in bacteriologically
evaluable patients
Organism N u m b er o f  isolates
S. aureus 15
Coagulase-negative staphylococci 5
S. pneumoniae 24
O ther streptococci 13
Acinetobacter spp. 6
Aerom onas  spp. 1
Citrobacter spp. 3
Enterobacter spp. 7
E. coli 9
Haemophilus spp. 19
Klebsiella spp. 21
M . catarrhalis 2
Proteus spp. 7
Serratia  spp. 2
O ther G ram -negative  bacilli" 1
Neisseria spp. 4
Corvnebacterium  spp. 1
Bacteroides spp. 2
"Gram stain identification without subculture.
Bacteriological results
A total of 142 pathogens was isolated before treatment from the 106 bacteriologically 
evaluable patients (Table III). In most patients only one pathogen was isolated 
(80/106). Eighteen patients had two pathogens, six patients had three and two patients 
had four.
The most prevalent organisms were Streptococcus pneumoniae with 24 out of the 142 
isolates (17%), Klebsiella pneumoniae with 18 isolates (13%) and H. influenzae with 17 
isolates ( 1 2 %).
Among the 142 pathogens, 15 were piperacillin-resistant, but susceptible to pipera­
cillin/tazobactam. These were isolated from 14 bacteriologically evaluable patients. The 
commonest pathogen of this type was Staphylococcus aureus (n = 7), followed by 
coagulase-negative staphylococci (n = 4), K. pneumoniae (n = 1), Klebsiella oxytoca 
(n = 1), Proteus morganii (n = 1) and Neisseria sp. (n = 1).
Clinical efficacy
The clinical response of the 133 clinically evaluable patients on the last day of therapy, 
and at the early and late follow-up evaluations are shown in Table IV.
At the early follow-up, 131 of the 133 evaluable patients had an interpretable 
response. Of these, 127 were clinically cured (111 of 131; 85%) or improved (16 of 131; 
12%), while 4 patients (3%) failed therapy. Patients with bronchopneumonia, unde­
fined lower respiratory tract infection (site of infection not determined) or pneumonia 
with pleurisy were all cured; 8 6  of 8 8  patients with pneumonia were also cured or 
improved. In the 25 patients with bronchitis, two (8 %) failed therapy.
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Table IV. Clinical response am ong  evaluable patients
O utcom e Last day o f  therapy Early follow-up Late follow-up
Cure 114 1 1 1 72
Im provem ent 13 16 1
Relapse l 2
Failure 4 4
Total 133 131 75
A total o f 75 patients returned for a late assessment. O f these 73 were assessed as 
cured or improved while two relapsed: one case of bronchitis was classified as relapsed 
because o f persistence of the original pathogen; the other had a relapse of pneumonia 
due to a reinfection.
Bacteriological response
O f 106 bacteriologically evaluable patients, 104 attended for early follow-up. The 
pathogen was presumptively eradicated in 47 patients. Among the remainder, eradica­
tion was documented in 50, the original pathogen persisted in 4 and there were three 
superinfections (Table V).
The four isolates which persisted at early follow-up were Streptococcus pyogenes,
S. aureus and two Acinetobacter spp.
At the late follow-up, 66 patients returned for assessment. O f these, 60 (91%) had a 
favourable response (presumed or documented eradication) while two patients (3%) 
showed evidence of persistence and four patients (6 %) had a reinfection. The two 
persisting organisms were S. aureus and S. pneumoniae. The latter organism had been 
presumed eradicated at early follow-up.
Among the 15 patients with pathogens that were piperacillin-resistant but susceptible 
to piperacillin/tazobactam , 14 were evaluable for early follow-up. All pathogens were 
eradicated; of 11 patients attending late follow-up, only one showed persistence 
(S. aureus).
The bacteriological responses o f all patients attending early and late follow-up are 
summarized for each diagnostic category in Table VI.
Table V. Bacteriological response am ong  bacteriologically evaluable patients
O utcom e Early follow-up Late follow-up
D ocum ented  eradication 50 25
Presum ptive eradication 47 35
Persistence 4 2
Superinfection 3
Re-infection 4
N o follow up 2 40
Total 106 106
Table VI. Bacteriological responses in patients attending early and late follow-up by the primary diagnosis
Diagnosis total
Early follow-up 
eradication persistence superinfection total
Late follow-up 
eradication persistence reinfection
Pneumonia 68 65 2 1 52 49 1 2
Bronchitis 21 20 1 0 8 7 1 0
Bronchopneumonia 9 8 0 1 4 3 0 1
Pneumonia with pleurisy 1 1 0 0 0 0 0 0
Undefined lower respiratory 5 3 1 1 2 1 0 1
tract infection"
Total 104 97 4 3 66 60 2 4
"Site of infection not determined.
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Duration o f  therapy
The mean duration of treatment was 9-1 days for all patients, 9*6 days for clinically 
evaluable patients and 10-0  days for bacteriologically evaluable patients.
Mortality
r
Sixteen patients died during or within 30 days of treatment with piperacillin/ 
tazobactam. In only one patient was death thought to be possibly drug related: he died 
on the third day of therapy from acute infection and lack of efficacy of the study drug.
Adverse reactions
Thirty-six of the 230 patients enrolled reported a total of 54 adverse events. The 
commonest side-effects were diarrhoea (17), stool changes (3), vomiting (2), erythema 
(3), exanthema (1), rash (2) and urticaria (1). In nine patients, a total of 17 adverse 
experiences necessitated permanent discontinuation of therapy.
Eighty laboratory test abnormalities definitely, possibly or probably related to study 
therapy were reported. Twenty were classified as haematological (platelet or eosinophil 
counts outside the normal range); 46 involved serum chemistry (abnormal liver 
function tests), three involved urinalysis and 11 involved tests of coagulation.
Discussion
Piperacillin sodium has been widely used in the treatment of severe lower respiratory 
tract infection (Mouton et al., 1986), but its efficacy is now limited against some 
^-lactamase producing organisms, such as S. aureus, H. influenzae, M. catarrhalis, or 
hospital-acquired Gram-negative bacilli.
The two main strategies are used to deal with this problem of /Mactamase mediated 
antibiotic resistance: use of new /2-lactam drugs able to withstand enzymatic inactiva­
tion; or combined administration of /2-lactam antibiotics and /2-lactamase inhibitors.
An example of the latter approach is use of the combination of piperacillin and 
tazobactam. The spectrum of activity of this combination extends to most of pathogens 
involved in pneumonia or bronchitis (Kuck et al., 1989; Weiss et a l 1989). Thus, it 
seems appropriate to test this combination in the therapy of lower respiratory tract 
infections and this was the purpose of this study.
The clinical response of the 133 clinically evaluable patients was impressive since the 
outcome was favourable in 127 patients (96%). The bacteriological response in the 
bacteriologically evaluable patients was also good since, at the early follow-up, only 
four of the 142 pathogens persisted. Moreover, all 15 piperacillin-resistant, piperacillin/ 
tazobactam-susceptible pathogens were eradicated.
The overall incidence of adverse experiences in this trial was not unlike those 
reported for piperacillin alone and for other /2-lactam antibiotics (Drusano, Schimpff & 
Hewitt, 1984). Piperacillin/tazobactam appears to be a safe and effective drug for the 
treatment of serious lower respiratory tract infection in hospitalized patients.
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